Danny Glover ‘Acting’ as Spokesman for Anemia LifeLine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

NEW YORK-Actor Danny Glover is serving as spokesman for Anemia LifeLine, a new educational initiative. Mr. Glover’s father had anemia associated with chronic kidney disease. At a press conference to launch the initiative, Mr. Glover told how anemia had robbed his father James Glover of his desire to do the things he loved. He said his father was ready to give up, but treatment gave him back his energy and independence.

NEW YORK—Actor Danny Glover is serving as spokesman for Anemia LifeLine, a new educational initiative. Mr. Glover’s father had anemia associated with chronic kidney disease. At a press conference to launch the initiative, Mr. Glover told how anemia had robbed his father James Glover of his desire to do the things he loved. He said his father was ready to give up, but treatment gave him back his energy and independence.

Anemia LifeLine was developed by Amgen Inc. in collaboration with the National Kidney Foundation; The Wellness Community, a national support group for cancer patients; and the National Anemia Action Council, representing various clinical specialties.

The campaign was designed to increase awareness of the signs and symptoms of anemia associated with serious disease, provide educational materials, encourage people to seek treatment, and demonstrate that treatment can lead to a healthier, more productive life.

Mr. Glover will make appearances throughout the country at National Kidney Foundation Kidney Walks and at anemia awareness events at malls. He will be featured in public service announcements and in educational materials available via a toll-free line (1-888-722-4407) and on the web (www.anemia.com). 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.